Published in PLoS One on February 12, 2016
A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med (2001) 9.98
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis (2001) 5.43
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis (2002) 4.43
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis (2011) 3.58
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One (2008) 3.13
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
How does HIV cause AIDS? Science (1993) 2.92
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Immunopathogenic mechanisms of HIV infection. Ann Intern Med (1996) 2.61
Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis (2008) 2.48
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr (2003) 1.69
A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med (2012) 1.68
Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med (2002) 1.66
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis (2010) 1.49
HIV-1 infection and low steady state viral loads. Bull Math Biol (2002) 1.46
Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database. J Antimicrob Chemother (2015) 1.44
Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One (2012) 1.44
Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials (2003) 1.36
A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns (2003) 1.28
Estimating the rate of accumulating drug resistance mutations in the HIV genome. Value Health (2007) 1.26
Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. J Acquir Immune Defic Syndr (2003) 1.18
HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med (2007) 1.11
Optimal drug treatment regimens for HIV depend on adherence. J Theor Biol (2007) 1.08
Averting HIV infections in New York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies. PLoS One (2013) 1.07
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol (2009) 0.98
Modeling HIV transmission risk among Mozambicans prior to their initiating highly active antiretroviral therapy. AIDS Care (2007) 0.92
Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLoS One (2014) 0.89
Patterns of adherence to raltegravir-based regimens and the risk of virological failure among HIV-infected patients: the RALTECAPS cohort study. J Acquir Immune Defic Syndr (2012) 0.89
HIV Viral Load Monitoring Frequency and Risk of Treatment Failure among Immunologically Stable HIV-Infected Patients Prescribed Combination Antiretroviral Therapy. J Int Assoc Provid AIDS Care (2015) 0.85
Modelling HIV and MTB co-infection including combined treatment strategies. PLoS One (2012) 0.83
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. PLoS One (2013) 0.82
Determinants of sexual network structure and their impact on cumulative network measures. PLoS Comput Biol (2012) 0.81
Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. PLoS One (2012) 0.77
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med (2015) 0.97
Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS One (2014) 0.80
Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study. Adv Ther (2016) 0.76
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLoS One (2016) 0.75
Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study. Pharmacoeconom Open (2021) 0.75
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One (2017) 0.75
Social and economic value of Portuguese community pharmacies in health care. BMC Health Serv Res (2017) 0.75